Application of “Systems Vaccinology” to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines

Figure 6

Illustration of need to identify a “safety boundary” on the sliding scale of adverse effects or biomarkers observed in response to “known to be safe” vaccines, immune agonists, and natural infection in animal models and human experimental medicine.